Busulphan

Pediatric Disorders

M.D. Anderson Cancer CenterPhase 1Dormant

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 95/ 100

Competitive context

0 Active assets in the Pediatric Disorders cohort.

Asset / Sponsor	Phase	Rating
Monomethyl Fumarate M.D. Anderson Cancer Center	Phase 1	CC
Thiotepa M.D. Anderson Cancer Center	Phase 1	CC
Cyclophosphamide M.D. Anderson Cancer Center	Phase 1	CC
TACROLIMUS M.D. Anderson Cancer Center	Phase 1	CC
ETOPOSIDE M.D. Anderson Cancer Center	Phase 1	CC

View all 10 →

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant

BBB

Indicative ·

77 / 100

myelodysplastic/myeloproliferative neoplasmDormant

BBB

Indicative ·

76 / 100

graft versus host diseaseDormant

BBB

Indicative ·

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.